「微元合成」获近3亿元融资，以甲醇为原料、开发大宗生物基产品

Group 1 - The core viewpoint of the article is that "微元合成" has recently secured nearly 300 million yuan in a new round of equity financing, with the funds aimed at accelerating the research and development of methanol-based biomanufacturing products [1][2] - The company has made significant progress in the development and commercialization of human and animal nutrition products, including allulose, lutein, and mannitol [1] - The financing will focus on the strategic area of "methanol biomanufacturing," with the company having already developed multiple high-efficiency methanol-assimilating strains [2][3] Group 2 - The company has received administrative approval from the National Health Commission for the production of allulose through a unique fermentation process, making it the first in China to do so [1][2] - The innovative "one-step fermentation method" simplifies the production process and significantly reduces costs compared to traditional methods [2] - The global production of chemical products is approximately 2.3 billion tons annually, while biobased products account for only 180 million tons, highlighting the need for non-food carbon sources in biomanufacturing [3] Group 3 - Methanol is identified as an ideal alternative carbon source, with China's coal-to-methanol capacity exceeding 10 million tons, representing 67% of the global total [3] - The company aims to utilize methanol to produce bulk amino acids, thereby reducing reliance on imported soybean meal and ensuring food security [3] - The development of non-food biobased products, particularly using agricultural residues and carbon dioxide, is gaining industry attention despite challenges in cost and logistics [3]